Question · asked by 1 review
Systemic beta carotene or carotenoids (incl. lycopene) vs placebo or no treatment: Safety of the intervention (adverse effects)
- Population
- People with a diagnosis of oral leukoplakia
- Intervention
- Systemic beta carotene or carotenoids (incl. lycopene)
- Comparison
- placebo or no treatment
- Outcome
- Safety of the intervention (adverse effects)
What each review found
Current versions onlyNo studies found 0 · 0%GRADE not reported 4 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Systemic beta carotene or carotenoids (incl. lycopene) vs Placebo or no treatment Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia · 5 to 12 months Interventions for treating oral leukoplakia to prevent oral cancer (2016) · Cochrane All outcomes | SoF 2, Safety of the intervention at 5 to 12 months: 'Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d (Nagao), and caused adverse effects of varying severity in 9% of… | 3 studies | GRADE not reported |
Systemic beta carotene or carotenoids (incl. lycopene) vs Placebo or no treatment Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia Interventions for treating oral leukoplakia to prevent oral cancer (2006) · Cochrane All outcomesearlier version CD001829.PUB3, superseded | Adverse effects (Table 1): beta carotene 360 mg/wk 9%; lycopene 8 or 4 mg (Singh) 0/40 vs 0/18, no adverse effects. | 2 studies | GRADE not reported |
Systemic beta carotene or carotenoids (incl. lycopene) vs Placebo or no treatment Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia Interventions for treating oral leukoplakia to prevent oral cancer (2004) · Cochrane All outcomesearlier version CD001829.PUB2, superseded | Adverse effects (Table 1): beta carotene 360 mg/wk 5/55 vs 1/55 (9%). | 1 study | GRADE not reported |
Systemic beta carotene or carotenoids (incl. lycopene) vs Placebo or no treatment Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia Interventions for treating oral leukoplakia to prevent oral cancer (1999) · Cochrane All outcomesearlier version CD001829, superseded | Adverse effects (Table 1): beta carotene 360 mg/wk (Sankaranarayan) 5/55 vs 1/55 (9%). | 1 study | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes | 2016-05 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.